Your browser doesn't support javascript.
Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys.
Al-Abri, Seif Salem; Al-Wahaibi, Adil; Al-Kindi, Hanan; Kurup, Padmamohan J; Al-Maqbali, Ali; Al-Mayahi, Zayid; Al-Tobi, Mohammed Hamed; Al-Katheri, Salim Habbash; Albusaidi, Sultan; Al-Sukaiti, Mahmood Humaid; Al Balushi, Ahmed Yar Mohammed; Abdelgadir, Iyad Omer; Al-Shehi, Nawal; Morkos, Essam; Al-Maani, Amal; Al-Rawahi, Bader; Alyaquobi, Fatma; Alqayoudhi, Abdullah; Al-Harthy, Khalid; Al-Khalili, Sulien; Al-Rashdi, Azza; Al-Shukri, Intisar; Al Ghafri, Thamra S; Al-Hashmi, Fatma; Al Jassasi, Saeed Mussalam; Alshaqsi, Nasser; Mitra, Nilanjan; Al Aamry, Humaid Suhail; Shah, Parag; Al Marbouai, Hanan Hassan; Al Araimi, Amany Hamed; Kair, Ismail Mohammed; Al Manji, Asim Mohammed; Almallak, Ahmed Said; Al Alawi, Fatma Khamis; Vaidya, Vidyanand; Muqeetullah, Muhammad; Alrashdi, Hanan; Al Jamoudi, Saud Said Nassir; Alshaqsi, Asila; Al Sharji, Abdullah; Al Shukeiri, Hamida; Al-Abri, Badr; Al-Rawahi, Sulaiman; Al-Lamki, Said H; Al-Manji, Abdulla; Al-Jardani, Amina.
  • Al-Abri SS; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman. Electronic address: salabri@gmail.com.
  • Al-Wahaibi A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Kindi H; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Kurup PJ; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Maqbali A; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Al-Mayahi Z; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Al-Tobi MH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Al-Katheri SH; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Albusaidi S; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al-Sukaiti MH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhahira Governorate, Ministry of Health, Ibri, Oman.
  • Al Balushi AYM; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Abdelgadir IO; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Al-Shehi N; Department of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman.
  • Morkos E; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Wusta Governorate, Ministry of Health, Haima, Oman.
  • Al-Maani A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rawahi B; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Alyaquobi F; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Alqayoudhi A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Harthy K; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Khalili S; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rashdi A; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Shukri I; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al Ghafri TS; Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Hashmi F; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Al Jassasi SM; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhahira Governorate, Ministry of Health, Ibri, Oman.
  • Alshaqsi N; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Mitra N; Department of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman.
  • Al Aamry HS; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Shah P; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al Marbouai HH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Al Araimi AH; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Kair IM; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Al Manji AM; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Almallak AS; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Al Alawi FK; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Vaidya V; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Muqeetullah M; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Alrashdi H; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al Jamoudi SSN; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Alshaqsi A; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Al Sharji A; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al Shukeiri H; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Abri B; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rawahi S; Health Services, Petroleum Development Oman, Muscat, Oman.
  • Al-Lamki SH; Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman.
  • Al-Manji A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Jardani A; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
Int J Infect Dis ; 112: 269-277, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1654549
ABSTRACT

OBJECTIVE:

To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic.

METHODS:

This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors.

RESULTS:

In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35).

CONCLUSION:

This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article